CHEK2 and ductal breast carcinoma in situ: found that 5/16 (31%) of women with DCIS and CHEK2 mutations developed contralateral disease (13) and a recent study of germline variants in patients with second breast cancers found that CHEK2 was the most frequently mutated gene in women with second breast cancers (3.4%) (14).